Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease

Alzheimer's and Dementia

Volumn 11, Issue 5, 2015, Pages 511-522

  Bertens, Daniela ^a   Knol, Dirk L ^b   Scheltens, Philip ^a   Visser, Pieter Jelle ^a,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Alzheimer's disease; Asymptomatic; Biomarkers; Cognitive markers; Dementia; Longitudinal; MCI; Observational

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); FLUORODEOXYGLUCOSE F 18; PEPTIDE FRAGMENT; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; COGNITIVE DEFECT; DIAGNOSTIC IMAGING; IMAGE PROCESSING; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; COGNITIVE DYSFUNCTION; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; TAU PROTEINS;

EID: 84929268024     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2014.05.1754     Document Type: Article

References (50)

1. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, and M.W. Weiner Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol 9 2010 119 128
2. B. Dubois, H.H. Feldman, C. Jacova, J.L. Cummings, S.T. Dekosky, and P. Barberger-Gateau Revising the definition of Alzheimer's disease: a new lexicon Lancet Neurol 9 2010 1118 1127
3. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, and A.M. Fagan Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 280 292
4. P.J. Visser, S. Vos, I. van Rossum, and P. Scheltens Comparison of International Working Group criteria and National Institute on Aging-Alzheimer's Association criteria for Alzheimer's disease Alzheimers Dement 8 2012 560 563
5. L. Berg Clinical Dementia Rating (CDR) Psychopharmacol Bull 24 1988 637 639
6. M.F. Folstein, S.E. Folstein, and P.R. McHugh "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 1975 189 198
7. W.G. Rosen, R.C. Mohs, and K.L. Davis A new rating scale for Alzheimer's disease Am J Psychiatry 141 1984 1356 1364
8. P.K. Crane, A. Carle, L.E. Gibbons, P. Insel, R.S. Mackin, and A. Gross Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Brain Imaging Behav 6 2012 502 516
9. L.E. Gibbons, A.C. Carle, R.S. Mackin, D. Harvey, S. Mukherjee, and P. Insel A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment Brain Imaging Behav 6 2012 517 527
10. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M. Stadlan Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 34 1984 939 944
11. V.C. Hachinski, L.D. Iliff, E. Zilhka, G.H. Du Boulay, V.L. McAllister, and J. Marshall Cerebral blood flow in dementia Arch Neurol 32 1975 632 637
12. J. Sheikh, and J. Yesavage Geriatric Depression Scale (GDS): recent evidence and development of a shorter version Clinical Gerontology: A Guide to Assessment and Intervention 1986 The Haworth Press New York 165 173
13. L.M. Shaw, H. Vanderstichele, M. Knapik-Czajka, C.M. Clark, P.S. Aisen, and R.C. Petersen Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects Ann Neurol 65 2009 403 413
14. P.A. Freeborough, and N.C. Fox The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI IEEE Trans Med Imaging 16 1997 623 629
15. K.K. Leung, M.J. Clarkson, J.W. Bartlett, S. Clegg, C.R. Jack Jr., and M.W. Weiner Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection Neuroimage 50 2010 516 523
16. B. Fischl, D.H. Salat, E. Busa, M. Albert, M. Dieterich, and C. Haselgrove Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain Neuron 33 2002 341 355
17. M. Reuter, N.J. Schmansky, H.D. Rosas, and B. Fischl Within-subject template estimation for unbiased longitudinal image analysis Neuroimage 61 2012 1402 1418
18. S.M. Landau, D. Harvey, C.M. Madison, R.A. Koeppe, E.M. Reiman, and N.L. Foster Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI Neurobiol Aging 32 2011 1207 1218
19. Y. Benjamini, and Y. Hochberg Controlling the false discovery rate: a practical and powerful approach to multiple testing J R Stat Soc Series B 57 1995 289 300
20. R.S. Desikan, L.K. McEvoy, W.K. Thompson, D. Holland, J.B. Brewer, and P.S. Aisen Amyloid-beta-associated clinical decline occurs only in the presence of elevated P-tau Arch Neurol 69 2012 709 713
21. S.J. Vos, C. Xiong, P.J. Visser, M.S. Jasielec, J. Hassenstab, and E.A. Grant Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study Lancet Neurol 12 2013 957 965
22. D. Erten-Lyons, H.H. Dodge, R. Woltjer, L.C. Silbert, D.B. Howieson, and P. Kramer Neuropathologic basis of age-associated brain atrophy JAMA Neurol 70 2013 616 622
23. A.M. Fjell, K.B. Walhovd, C. Fennema-Notestine, L.K. McEvoy, D.J. Hagler, and D. Holland Brain atrophy in healthy aging is related to CSF levels of Abeta1-42 Cereb Cortex 20 2010 2069 2079
24. C.R. Jack Jr., D.S. Knopman, S.D. Weigand, H.J. Wiste, P. Vemuri, and V. Lowe An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease Ann Neurol 71 2012 765 775
25. J.A. Becker, T. Hedden, J. Carmasin, J. Maye, D.M. Rentz, and D. Putcha Amyloid-beta associated cortical thinning in clinically normal elderly Ann Neurol 69 2011 1032 1042
26. A.M. Fagan, D. Head, A.R. Shah, D. Marcus, M. Mintun, and J.C. Morris Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly Ann Neurol 65 2009 176 183
27. M. Storandt, M.A. Mintun, D. Head, and J.C. Morris Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition Arch Neurol 66 2009 1476 1481
28. J.M. Schott, J.W. Bartlett, N.C. Fox, and J. Barnes Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Abeta1-42 Ann Neurol 68 2010 825 834
29. T. Hedden, H. Oh, A.P. Younger, and T.A. Patel Meta-analysis of amyloid-cognition relations in cognitively normal older adults Neurology 80 2013 1341 1348
30. S.M. Resnick, J. Sojkova, Y. Zhou, Y. An, W. Ye, and D.P. Holt Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB Neurology 74 2010 807 815
31. M. Ewers, P. Insel, W.J. Jagust, L. Shaw, J.Q. Trojanowski, and P. Aisen CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects Cereb Cortex 22 2012 1993 2004
32. V.L. Villemagne, S. Burnham, P. Bourgeat, B. Brown, K.A. Ellis, and O. Salvado Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study Lancet Neurol 12 2013 357 367
33. C.R. Jack Jr., M.M. Shiung, S.D. Weigand, P.C. O'Brien, J.L. Gunter, and B.F. Boeve Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI Neurology 65 2005 1227 1231
34. J.D. Sluimer, W.M. van der Flier, G.B. Karas, N.C. Fox, P. Scheltens, and F. Barkhof Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients Radiology 248 2008 590 598
35. M.C. Evans, J. Barnes, C. Nielsen, L.G. Kim, S.L. Clegg, and M. Blair Volume changes in Alzheimer's disease and mild cognitive impairment: cognitive associations Eur Radiol 20 2010 674 682
36. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, R.C. Petersen, M.W. Weiner, and P.S. Aisen Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers Lancet Neurol 12 2013 207 216
37. N. Andreasen, C. Hesse, P. Davidsson, L. Minthon, A. Wallin, and B. Winblad Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease Arch Neurol 56 1999 673 680
38. P. Vemuri, H.J. Wiste, S.D. Weigand, D.S. Knopman, J.Q. Trojanowski, and L.M. Shaw Serial MRI and CSF biomarkers in normal aging, MCI, and AD Neurology 75 2010 143 151
39. N. Mattsson, E. Portelius, S. Rolstad, M. Gustavsson, U. Andreasson, and M. Stridsberg Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment J Alzheimers Dis 30 2012 767 778
40. K. Burger nee Buch, F. Padberg, T. Nolde, S.J. Teipel, S. Stubner, and A. Haslinger Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old patients with Alzheimer's disease compared with controls Neurosci Lett 277 1999 21 24
41. D. Holland, R.S. Desikan, A.M. Dale, and L.K. McEvoy Rates of decline in Alzheimer disease decrease with age PLoS One 7 2012 e42325
42. N. Mattsson, E. Rosen, O. Hansson, N. Andreasen, L. Parnetti, and M. Jonsson Age and diagnostic performance of Alzheimer disease CSF biomarkers Neurology 78 2012 468 476
43. I.A. van Rossum, S.J. Vos, L. Burns, D.L. Knol, P. Scheltens, and H. Soininen Injury markers predict time to dementia in subjects with MCI and amyloid pathology Neurology 79 2012 1809 1816
44. S. Vos, I. van Rossum, L. Burns, D. Knol, P. Scheltens, and H. Soininen Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI Neurobiol Aging 33 2012 2272 2281
45. L. Wang, A.M. Fagan, A.R. Shah, M.F. Beg, J.G. Csernansky, and J.C. Morris Cerebrospinal fluid proteins predict longitudinal hippocampal degeneration in early-stage dementia of the Alzheimer type Alzheimer Dis Assoc Disord 26 2012 314 321
46. A. Caroli, and G.B. Frisoni The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort Neurobiol Aging 31 2010 1263 1274
47. J. Nettiksimmons, D. Harvey, J. Brewer, O. Carmichael, C. DeCarli, and C.R. Jack Jr. Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline Neurobiol Aging 31 2010 1419 1428
48. C.R. Jack Jr., P. Vemuri, H.J. Wiste, S.D. Weigand, P.S. Aisen, and J.Q. Trojanowski Evidence for ordering of Alzheimer disease biomarkers Arch Neurol 68 2011 1526 1535
49. R.Y. Lo, A.E. Hubbard, L.M. Shaw, J.Q. Trojanowski, R.C. Petersen, and P.S. Aisen Longitudinal change of biomarkers in cognitive decline Arch Neurol 68 2011 1257 1266
50. C.R. Jack Jr., P. Vemuri, H.J. Wiste, S.D. Weigand, T.G. Lesnick, and V. Lowe Shapes of the trajectories of 5 major biomarkers of Alzheimer disease Arch Neurol 69 2012 856 867